Twitter Facebook YouTube Google+ LinkedIn RSS Feed

HLA-B*5801 Genotype, Allopurinol Hypersensitivity [A Test in Focus]

Mayo Medical Laboratories is excited to announce the availability of a new test. Below are some of the key aspects of the new test for your quick review.

Also available for your reference is a detailed test information sheet.




  • Predicting increased risk of hypersensitivity reactions to allopurinol
  • Excluding patients at an elevated risk for allopurinol hypersensitivity syndrome from receiving allopurinol
  • Allopurinol is widely used for hyperuricemia-related diseases such as gout, Lesch-Nyhan syndrome, and recurrent urate kidney stones.
  • There is a reported mortality rate of 20% to 25% for allopurinol hypersensitivity syndrome (AHS).
  • Guidelines have been developed by the Clinical Pharmacogenomics Implementation Consortium that reviewed the literature that supports HLA-B*5801 genotyping prior to use of allopurinol. The consortium recommend that allopurinol should not be prescribed to patients who test positive for the allele.
  • Guidelines developed by the 2012 American College of Rheumatology for Management of Gout recommend that HLA-B*5801 testing should be considered in select patient subpopulations at an elevated risk for AHS.
  • Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)


  • Day(s) and Time(s) Test Performed: Monday and Thursday
  • Analytic Time: 1 day

About Andy Tofilon

Andy is a Marketing Segment Manager for Mayo Medical Laboratories.
This entry was posted in A Test in Focus, Genetics, Pharmacogenomics, Testing.